NOW ENROLLING:
OCEAN study for adults with EGPA
Do you have eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome? The OCEAN clinical research study is looking for participants who are 18 years of age or older with EGPA that has worsened or returned after previous treatment. See if you’re eligible by taking this 10 minute survey.
Take The SurveyAbout the OCEAN Study
The OCEAN study is testing an investigational drug to see how it works in adults with EGPA that has worsened or returned after previous treatment. An investigational drug is one that is not yet approved for use by the general public.
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is a condition caused by inflammation as a result of high numbers of certain types of cells in your blood or in your tissues. In most people, EGPA affects the lungs, causing breathing and lung issues, but it can also affect other organs in the body. The exact cause of EGPA is unknown, but an overactive immune system may cause inflammation.
Who can participate in the OCEAN study?
You may qualify for the OCEAN study if you:
-
Are at least 18 years of age or older
-
Have EGPA that has worsened or returned after previous treatment
-
Are currently taking a corticosteroid or immunosuppressant treatment
This is not a complete list of study requirements. The study doctor will review the full requirements for this study with you.
Take The SurveyWhat can I expect if I decide to participate?
If you qualify, you will be involved with the study approximately 60 weeks (a little over 1 year).
Screening Period
(1 to 4 weeks)- You will be asked about your history of EGPA and treatment
- Go over your general medical history
- Go over electronic Diary (eDiary) registration and training
Study Treatment Period
(52 weeks)- You will be randomly assigned (by chance; like flipping a coin) to a study group to receive either the investigational study drug (depemokimab) or mepolizumab (a drug approved to treat EGPA).
- Either the study drug (depemokimab) or mepolizumab will be given as injections during the 52-week treatment period.
- Both study groups will also receive placebo injections plus standard EGPA therapy as prescribed by a doctor.
Follow-Up Period
(After about 4 weeks)- You will stop receiving the study drug (depemokimab) or mepolizumab
- You will receive a follow-up phone call about 4 weeks after your last study injections so study staff can ask you safety questions.
What safeguards are in place to help protect study participants?
There are rules in place to help protect the rights, safety, and well-being of people who volunteer for research studies. These rules are put in place to make sure studies follow strict scientific and ethical guidelines. Before a clinical research study can begin, a review board must review the study. This group is called an IRB or institutional review board, and is made up of doctors, scientists, and members of the community.
See if you’re eligible for the OCEAN study by taking this 10 minute survey.
Take The Survey →Is participation mandatory?
Does it cost anything?
Taking part in this study is totally voluntary and you may stop at any time for any reason. Additionally during the study, you do not have to pay for the study drug or mepolizumab, study supplies, or tests that are part of the OCEAN study.
What is a Research Study?
Before new treatments and medications are made available to the public, they first have to be studied to make sure they’re safe and effective. That’s where research studies come in. A research study, or clinical trial, is a type of medical research that’s used to determine how well a new treatment or medication will work. The goal is simple: To help doctors find safe and effective ways to treat, diagnose or even prevent all kinds of medical conditions.
Learn More
